Machine Learning in Cardiovascular Medicine 2021
DOI: 10.1016/b978-0-12-820273-9.00014-2
|View full text |Cite
|
Sign up to set email alerts
|

Machine learning in cardiovascular genomics, proteomics, and drug discovery

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1
1

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 91 publications
0
1
0
Order By: Relevance
“…Even though there are still many obstacles to overcome, current initiatives for the discovery and development of disease-related biomarkers will help with the best decision-making during the medication development process and further our comprehension of the disease processes. To the benefit of patients, healthcare professionals, and the biopharmaceutical industry, good preclinical biomarker translation into the clinic will pave the path for the effective execution of personalized therapies across a range of complex disease areas [63,64]. Figure 5 illustrates the distribution of the all studies focusing on each area of application.…”
Section: Cmentioning
confidence: 99%
“…Even though there are still many obstacles to overcome, current initiatives for the discovery and development of disease-related biomarkers will help with the best decision-making during the medication development process and further our comprehension of the disease processes. To the benefit of patients, healthcare professionals, and the biopharmaceutical industry, good preclinical biomarker translation into the clinic will pave the path for the effective execution of personalized therapies across a range of complex disease areas [63,64]. Figure 5 illustrates the distribution of the all studies focusing on each area of application.…”
Section: Cmentioning
confidence: 99%